Home Neoplasma 2020 Neoplasma Vol.67, No.1, p.178–184, 2020

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.67, No.1, p.178–184, 2020

Title: Bortezomib retreatment is effective in relapsed multiple myeloma patients – real-life clinical practice data
Author: M. Stork, S. Sevcikova, L. Brozova, I. Spicka, V. Maisnar, J. Minarik, A. Jungova, E. Gregora, R. Velichova, R. Hajek, T. Jelinek, L. Pour

Abstract: Nowadays, bortezomib, a proteasome inhibitor, is widely used in treatment of newly diagnosed or relapsed multiple myeloma. The aim of this study was to analyze efficiency of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. From 2004 to 2016, 283 patients were retrospectively evaluated at all hematological centers in the Czech Republic. Bortezomib was administered at the standard dosing and in combined therapy with corticosteroids, chemotherapy or thalidomide. Before bortezomib retreatment, 61% of patients received previous lenalidomide treatment, 40.6% autologous transplantation, and median number of prior lines of therapy was three. In total, 21% of patients were refractory to the first bortezomib treatment. In bortezomib retreatment, overall response rate was 34.5%, median progression-free survival was 7.8 months (95% CI: 6.7–8.9), median duration of response was 10.5 months (95% CI: 8.0–13.0) and median overall survival was 20.3 months (95% CI: 17.9–22.7). Grade 3-4 adverse events included thrombocytopenia, neutropenia, anemia and infection. Neuropathy grade 2 or higher occurred in 19.4% of patients. We conclude that bortezomib retreatment is an effective and safe therapeutic alternative for relapsed or refractory multiple myeloma patients.

Keywords: multiple myeloma, bortezomib, proteasome inhibitor, repeated treatment, relapse
Published online: 29-Jan-2020
Year: 2020, Volume: 67, Issue: 1 Page From: 178, Page To: 184
doi:10.4149/neo_2019_190430N383
Price: 14.70 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.